GeNeuro (FRA:GEM) Valuation Rank


FRA:GEM GeNeuro SA FRA:GEM
8 GF Score
Price €0.03
View Full Analysis

What is GeNeuro Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

GeNeuro Valuation Rank Related Terms

FRA:GEM
8GF Score
GeNeuro SA FRA:GEM
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeNeuro Business Description

Address 3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
8GF Score

Get the complete analysis for FRA:GEM

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price